Document is current
Any future updates will be listed below
-
Authors
Moore, Kathleen S.
Stipho, Yara S.
Niemann, Nicki
Shill, Holly A.
Chan, Justine
Abrego, Crystal J.
Eagan, Danielle
Decourt, Boris
Sabbagh, Marwan N. https://orcid.org/0000-0001-8139-3309
-
Funding
Funding for this research was provided by:
National Institutes of Health - Department of Bioethics (R01AG059008)
National Institutes of Health - Department of Bioethics (R01AG073212)
National Institutes of Health - Department of Bioethics (P30 AG072980)
Alzheimer's Drug Discovery Foundation (GC-2013717)
Barrow Neurological Foundation
- License Information
-
More Information
Article History
Received: 21 August 2025
Accepted: 19 December 2025
First Online: 19 January 2026
Declarations
:
: Marwan N. Sabbagh is a consultant for Alzheon, Athira, Biogen, Roche-Genentech, Eisai, Synaptogenix, NeuroTherapia, Cognito Therapeutics, Signant Health, and Novo Nordisk; is also an editorial board member of Neurology and Therapy , but was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Boris Decourt is a consultant for Lighthouse Pharmaceuticals. Nicki Niemann receives research support from The Michael J. Fox Foundation for Parkinson’s Research, F. Hoffman-La Roche Ltd, Intra-Cellular Therapies Inc., Bial R&D Investments S.A., and Impax Laboratories LLC. Holly A. Shill has received research support from Intra-cellular Therapeutics, Parkinson Study Group/UCB, Parkinson’s Foundation, NINDS, MJFF, Jazz Pharmaceuticals, Fasikl, and Barrow Neurological Foundation. Holly A. Shill has served as a consultant for Biovie, Boston Scientific, Mitsubishi Tanabe, KeifeRx, Jazz, Fasikl, and Sumitomo. Kathleen S. Moore, Yara S. Stipho, Justine Chan, Crystal J. Abrego, and Danielle Eagan have nothing to disclose.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
